Home ›
Brain Cancer Trials ›
NCT06942039
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.
Trial Details
NCT ID NCT06942039
Phase EARLY_PHASE1
Sponsor C17 Council
Status RECRUITING
Cancer Type Brain Cancer
Interventions Cytarabine IT hydrocortisone Cisplatin Vincristine Etoposide Cyclophosphamide
Locations (sample) Calgary, Alberta, Canada|51.05011,-114.08529 Vancouver, British Columbia, Canada|49.24966,-123.11934 Winnipeg, Manitoba, Canada|49.8844,-97.14704 Halifax, Nova Scotia, Canada|44.64269,-63.57688 Hamilton, Ontario, Canada|43.25011,-79.84963
Key Eligibility Criteria
Tumor Tissue Sample Age: Patient must be aged ≥ 0 years to ≤ 6 years at the time of definitive confirmation of histologic diagnosis of eligible CNS tumor. Diagnoses. Participants must have Central nervous system (CNS) HR-EBT including atypical teratoid rhabdoid tumour (ATRT), group 3 and group 4 medul… Cranial and Spine MRI. A baseline MRI brain and spine with and without contrast is required for all patients. cranial MRI (with and without gadolin…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →